Xenetic Biosciences, Inc.
XBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Xenetic Biosciences, Inc. focuses on Biotechnology services and products. Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company carries a $6.4M market cap, placing it firmly in the micro-cap category. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Market Cap
$6.4M
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-4.22
EPS (TTM)
$-1.19
EPS (Fwd)
$-0.66
ROE
-37.0%
ROA
-21.9%
Cash
$7.3M
Total Debt
$0
Free CF
-$1.1M
52W Change
-24.0%
Annual Financials
Cash vs Debt
Xenetic Biosciences, Inc. reports $7.3M in cash and $0 in total debt. Free cash flow is running at -$1.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -37.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.7M (2022) to $3.0M (2025), reflecting a 74% increase over the period.
With a beta above 1.5, XBIO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Xenetic Biosciences, Inc. and its sector.